Talking Precision Medicine (Genialis)

Today’s episode is a bit different — different in that we are rejoined by a previous guest — David Mittelman. David is CEO of Othram, the first genomics-based forensics company. The audience response to our first conversation was so overwhelming we wanted to have David back on. And the timing couldn’t be better. Since our last chat, David and Othram have been all over the news, and have launched a new database product.

Visit ⁠TPM E18 for highlights and links from this episode.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today’s podcast is a special episode of Talking Precision Medicine, dedicated to the Alliance for Artificial Intelligence in Healthcare. The A-A-I-H saw its official hard launch at JP Morgan this past January, with a standing-room-only panel discussion at the Biotech Showcase. Our guest today is Dr. Annastasiah Mhaka, a Senior Advisor at Adjuvant Partners and the muscle behind standing up the AAIH.

The Alliance is a global organization that aims to improve patient quality of life by creating more effective, sustainable, and accessible healthcare. Through its work on education, regulatory issues, technology standards, and more, the AAIH will foster the responsible development of emerging industry segments poised to have a tremendous impact across the healthcare spectrum.

At the end of our conversation with Annastasiah, we include some bonus material recorded at The Future of AI-Powered Healthcare panel discussion at JPM.

Full disclosure— Genialis is a founding member of the AAIH, and its CEO, Rafael Rosengarten, is a board director.

Today my guest is Joydeep Goswami, newly appointed President and CEO of the storied biotechnology company LGC. Joydeep is also a strategy advisor to Genialis. Join us as we discuss his remarkable career and lessons learned at each step of the way.

Come on in and have a listen.

Episode 42 links:

• ⁠⁠⁠⁠⁠⁠⁠TPM E42⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠⁠⁠⁠
• Tempus Announces a Collaboration With Genialis
• Genialis’ Upcoming Events

Our guest this episode is Charles Fisher, co-founder and currently Chief Scientific Officer of Unlearn.AI. Unlearn has been a leader in the advancement of Digital Twins as a tool to drastically improve the efficiency of clinical trials. Not only a visionary scientist and trailblazing entrepreneur, Charles is fearless with his hot takes. So sit back and enjoy this free wheeling conversation!

Episode 40 links:

• ⁠⁠⁠⁠⁠⁠TPM E40⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠⁠
• Potential of the Xerna™ TME Panel as a Predictive Biomarker (SITC 2024 Poster)
• ⁠⁠⁠⁠Genialis’ Upcoming Events⁠⁠⁠⁠
• ⁠Genialis on LinkedIn

Our guests for this episode of Talking Precision Medicine are Elissa Prichep and Cameron Fox of the World Economic Forum. Elissa and Cameron take us through the W.E.F’s precision medicine initiative, and explain how anticipating ethical tensions is key to envisioning policies for precision medicine across the globe. 

Visit TPM E22 for highlights and links from this episode.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today we speak with Patrick Hanley. Patrick works at the Children’s National Hospital in Washington DC, where he serves as the director of Good Manufacturing Practices for Immunotherapy. He is also a co-founder and vice president at Mana Therapeutics — a cell therapy company harnessing our immune cells to combat cancer. He is an expert in designing and manufacturing cell therapies... and was once a fierce competitor on the Houston indoor soccer circuit. 

We talk about the leaps and bounds of progress in cell therapy, and the challenges—including discovery, manufacturing, and distribution—that lay ahead.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. 

Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today we speak with Mark Kiel. Mark is the founder and Chief Scientific Officer at Genomenon where he shepherds the product vision and implementation of the Mastermind suite of software tools.

He completed an MD / PhD  fellowship in Molecular Genetic Pathology at the University of Michigan. 

In this episode, Mark describes the genesis of his vision to organize the world’s molecular data and his journey to realize the promise of genomic medicine.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today we speak with Matthew Michelson. Matthew is CEO of Evid Science — a technology company using AI to make access to medical evidence as simple and seamless as possible. He is an expert in machine learning and natural language processing and an enthusiastic company builder. 

We talk about how Evid supports evidence-based medicine, the value of well curated information, and the importance of doing the work to validate your science.

What a pleasure to welcome today’s guest, Ryan Fukushima, chief operating officer of TempusAI. Not only has Ryan helped build Tempus brick by brick from the earliest days, he is also CEO of Pathos AI, a biotech company using real world data and AI to develop true precision medicines. I don’t know how he juggles it all, but unless you’ve been hiding out these last few years, Tempus has become a household name in our industry, completing a highly successful IPO last year. But no need to take my word for it, come on in and have a listen!

TPM E43 highlights >⁠⁠⁠⁠⁠⁠

Episode 43 links:

Ryan Fukushima on LinkedIn⁠

⁠Tempus AI⁠

⁠Pathos⁠

⁠Tempus announces multi-year collaboration with Genialis

In this episode, our host and Genialis CEO Rafael Rosengarten spotlights Vibe Bio. Vibe Bio is a new biotech aiming to disrupt how we finance drug development through stakeholder communities and cryptocurrency, starting in the rare disease arena. Our guest is Alok Tayi, co-founder and CEO of Vibe. Alok is a successful serial entrepreneur and a rare disease community member.

Visit TPM E28 for highlights and links from this episode.

In this episode, Genialis CEO Rafael Rosengarten speaks with BCG management consultant and healthcare innovation expert Amy MacDougall. They discuss emerging trends in healthcare, the role of AI, ethics and more, as well as BCG’s recently released 50 Most Innovative Companies List.

Visit TPM E31 for highlights and links from this episode.

This episode features two guests, Jennifer Goldsack and Yashoda Sharma, of the Digital Medicine Society, or DiMe. We’re going to get into the nitty gritty of healthcare disparities in terms of access and outcomes, and how digital solutions are a big part of the overall solution. 

Episode 36 links:

• ⁠⁠⁠TPM E36⁠⁠⁠ for highlights and links from this episode >
• Genialis’ Upcoming Events
• Genialis™ krasID

Our guest for this episode of Talking Precision Medicine is Liang Schweizer from HiFiBiO Therapeutics - one of the most exciting young biotechs out there. They have built a discovery engine encompassing single cell, immune profiling and machine learning.

Visit TPM E23 for highlights and links from this episode.

Today’s guests are Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss, Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development of advanced and personalized treatments.

TPM E45 highlights >⁠⁠⁠⁠⁠⁠⁠⁠

Episode 45 links:

• Anna Berkenblit on LinkedIn
• Sudheer Doss on LinkedIn
• PanCAN
• For access to data through PanCAN’s SPARK platform, please visit: PanCAN.org/spark
• For more information, contact PanCAN Patient Services with questions about any type of pancreatic cancer – we are here to help.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. 

Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today we speak with Julie Walters. Julie is the founder of Raremark, an information hub about rare disease for patients and their families. She has a degree in molecular genetics and a background in popular journalism… and is an entrepreneur by nature. In fact, she was a Female Entrepreneur of the Year at the UK’s 2017 Enterprise Awards. 

Julie believes in harnessing the power of families affected by a rare disease, and our discussion covers many of the ways Raremark aims to do just that. 

Our guest is Dr. Angeli Moeller, Head of Pharma International Informatics at Roche. Angeli and our host, Rafael, discuss data science in the big pharma leagues; geek out on data standards; and dive deep on patient data rights and barriers to care.

Visit TPM E24 for highlights and links from this episode.

In this episode 26, our host Rafael sits down with Harry Glorikian. Harry is an investor, author, podcaster and veteran of the healthtech industry. Harry walks us through his latest book, The Future You, and expounds on the ways that wearable devices, personal health data and artificial intelligence are changing healthcare as we know it.

Visit TPM E26 for highlights and links from this episode.

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. 

This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today our guest is Gabe Musso. Gabe is Chief Scientific Officer of BioSymetrics, a Toronto-based biomedical AI company empowering healthcare and R&D innovation. 

In this episode, Gabe tells us how BioSymetrics is working to clean up data clean up, by applying a rigorous product framework to data preprocessing. 

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics. Today we speak with Elia Stupka. Elia is the Chief Analytics Officer and Senior Vice President of the Life Sciences Business at Health Catalyst — a next-generation data, analytics, and decision-support company. He has deep experience leading interdisciplinary teams in academia and industry encompassing fields such as genomics, computational biology, data science, AI and NLP and is a true visionary leader with a passion for innovation in health and life sciences. At Health Catalyst Elia is leveraging company's data to advance the life sciences—from drug discovery to understanding the patient impact of specific medications. The conversation covers a lot of ground, including Elia’s take on: using data at the point of care; key challenges in making therapeutic innovation accessible to the population at large; and the importance of storytelling in work and in life. 

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics.

Today our guest is Yusuf Henriques. Yusuf is co-founder and CEO of TruGenomix, a precision medicine company focused on the early detection and prevention of PTSD in military veterans and first responders.

In this episode, Yusuf reminds us that every day counts. Because every day there are 20 to 22 veteran suicides. This is what keeps Yusuf up at night, and keeps him pushing on all fronts to innovate a solution.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. 

Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today we speak with Dr. Nicole Paulk. Nicole is an assistant professor at the University of California San Francisco, and the Advisory Lead for Genome Engineering at Chan Zuckerberg Biohub. 

Nicole’s lab builds technologies to advance the entire field of viral gene therapy. They are a force behind the rising tide lifting the gene therapy industry. She is also committed to training the next generation of scientist innovators. 

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today we speak with Olivier Elemento. Olivier is the Director of the Englander Institute for Precision Medicine, as well as Associate Director of the Institute for Computational Biomedicine, both at Weill Cornell Medicine. He is also co-founder of OneThree Biotech. Olivier is a practitioner par excellence, in applying advanced analytics to large genomic and patient datasets. 

Our conversation covered a lot of ground, including curated knowledge bases, patient consent, breakthroughs in preclinical models, and even AR/VR.

Earlier this summer, Rafael sat down with Peter Vranes and Hitesh Mehta, co-founders of Nutromics. Nutromics is developing a next generation lab-on-skin, a wearable device for continuous monitoring of health-critical biomarkers. Let’s get right to it.

Visit TPM 25 for highlights and links from this episode.

This episode features Jason Springs, co-founder and CEO of Endpoint Health, an ascendant precision therapeutics company. Jason is a serial entrepreneur, who with the co-founders of his previous company, is building Endpoint Health to bring together under one roof the data science, diagnostics and therapeutics necessary to achieve truly personalized care.

Visit TPM E27 for highlights and links from this episode.

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. 

This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today our guest is David Mittelman. David is CEO of Othram, the first genomics-based forensics company. David is also a serial genomics entrepreneur, and, like Genialis, based in Houston.

In this episode, David explains his vision for disrupting the state of the art in forensics identification using genomics, deep sequencing and machine learning. A bit of a departure from the usual themes around medical applications of data and data science.

In this episode, Genialis CEO Rafael Rosengarten sits down with Ajay Gopal, CEO and founder of Rx Studio. Rx Studio is a technology company using data science to tackle a major limitation to personalized medicine: drug dosing.

Visit TPM E32 for highlights and links from this episode.

Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating battlefield trauma? Only one way to find out …

Visit ⁠TPM E33⁠ for highlights and links from this episode.

This episode, Genialis’ thirtieth, is a bit different from the previous ones. CEO Rafael Rosengarten has not one, not two, but three guests, including the entire leadership team at Genialis. The gang discusses Genialis’ twin quests to build a great place to work and a business that makes a positive impact on the world. 

Visit TPM E30 for highlights and links from this episode.

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.

Episode 35 links:

• Visit ⁠⁠⁠TPM E35⁠⁠⁠ for highlights and links from this episode >
• Learn more about Genialis™ krasID >
• New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. 

Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today we speak with Luba Greenwood, who works in Strategic Business Development and Corporate Ventures at Verily, an Alphabet company. 

Luba brings to Google her experience in pharmaceutical, biotechnology, and digital health industries. Not to mention her expertise in building and investing in innovative technology companies. 

She is on the Board of MassBio and Brooklyn ImmunoTherapeutics, and serves as an Advisor to the Dana Farber Cancer Institute.

In this episode, we dive into Luba’s work across the intersections of healthcare and technology.

Today Rafael is joined by Dr. Sarma Velamuri, founder and CEO of Luminare. Luminare is a Houston-based digital health company dedicated to ending sepsis—the number 1 cause of death in US hospitals. In the conversation that follows, Dr. Velamuri explains how Luminare saves lives by streamlining hospital workflows, and by changing the behaviors of nurses and doctors. They’ve also made a giant leap into covid tracking, emerging as national leaders on this front.

Visit TPM E20 for  highlights and links from this episode.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.

Today we speak with Ethan Perlstein. Ethan is CEO at Perlara — a scientific discovery public benefit corporation that works with families, advocacy groups and BioPharma companies to develop cures for rare diseases. Perlara challenges the conventional approach to drug discovery through its scientific platform for evolutionary pharmacology.

We talk about Perlara’s approach to rare disease drug discovery; The power of working with families and foundations; as well as “Organic intelligence,” and what we can learn from biology. 

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. 

This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. 

Today our guest is Tina Larson. Tina is COO of Recursion Pharmaceuticals, where she is tasked with building the team, the operations and the culture to tackle Recursion’s audacious goals. Tina has over 20 years of experience in the biopharmaceutical industry, and was recently awarded the 2019 Distinguished Alumni Award from her alma mater Colorado State University.

In this episode, we talk about the language of multidisciplinary teams, recruiting top talent while fostering inclusivity, and the promise of melding tech and biology to advance treatments at unprecedented scale.

What a genuine pleasure to sit with Thierry Bernard, CEO of Qiagen. As I told Thierry, Qiagen is a truly iconic brand for anyone who came up through molecular biology laboratories in the past 30 years. Their products were ubiquitous, and crucial, to the success of our research. In this conversation, Thierry talks about his global vision for precision medicine, and his mantra that we leave no patient behind.

Episode 39 links:

• ⁠⁠⁠⁠⁠TPM E39⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠
• Genialis™ krasID Poster at 6th Annual RAS-Targeted Drug Development Summit 2024
• ⁠⁠⁠Genialis’ Upcoming Events⁠⁠⁠
• Genialis on LinkedIn

Our guest this episode is Dr. Susanna Harris, community lead at Vibe Bio. Susanna is a dedicated scientific communicator and an outspoken advocate for the mental health of PhD students and other science researchers. She has chronicled her journey from the academic lab bench to a venture incubator to a promising biotech company for a substantial social media following, and joins us today to dive into these topics and more.

Visit TPM E29 for highlights and links from this episode.

In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.

Episode 37 links:

• ⁠⁠⁠⁠TPM E37⁠⁠⁠ for highlights and links from this episode >⁠
• ⁠Genialis’ Upcoming Events⁠
• ⁠Genialis™ krasID

What a pleasure to sit down with my long time colleague and friend, Art Krieg, to discuss his latest venture, Zola Therapeutics, and his adventures in the great outdoors. Art has launched and exited a number of innovative biotechs, each time delving deeper into mechanisms by which we can harness the immune system for therapeutic purposes. Join us as we discuss how — despite a well earned retirement — the siren song that led to Zola was strong enough to get Art back in the game. 

Episode 38 links:

• ⁠⁠⁠⁠TPM E38⁠⁠⁠ for highlights and links from this episode >⁠⁠
• ⁠⁠Genialis’ Upcoming Events⁠⁠
• ⁠⁠Genialis™ krasID

Today we turn the mic around, as our guest Adam Stasio hosts an excellent podcast of his own. Adam’s day job, however, is running SciMed, a boutique life sciences software development company. Adam and Genialis CEO Rafael Rosengarten discuss the state of scientific software, the importance of agility and communication, and approaches to building a lasting company culture.

Visit ⁠⁠TPM E34⁠⁠ for highlights and links from this episode.

This episode features a conversation with Shweta Maniar, who leads the Healthcare and Life Science effort at Google cloud. In just a few short years, artificial intelligence has gone from the stuff of hype and fairy tale to powerful and ubiquitous tools for all aspects of R&D and healthcare delivery. Google has been central to this sea change. I discuss with Shweta how her organization helps make these advanced capabilities available to the masses, and so much more. Join us!

Episode 41 links:

• ⁠⁠⁠⁠⁠⁠⁠TPM E41⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠⁠
• Genialis™ Supermodel
• Happy Holidays
• Genialis' Upcoming Events
• Genialis on LinkedIn

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling in precision medicine. We help accelerate the discovery and de-risk the development of novel therapeutics. From heterogeneous data and diverse information stores, we predict with confidence drug targets and biomarkers of tolerance, efficacy and outcome. Today we speak with Jonny Wray. Jonny is the Head of Discovery Informatics at e-therapeutics—a network-driven drug discovery company. He has extensive experience in applying mathematical and computational techniques to the modeling and analysis of biological systems, and is responsible for the conceptual formulation of the network-driven drug discovery approach pioneered at e-Therapeutics. We talk about everything from appreciating the complexity of biology to mechanistic modeling to discovering an entirely new chemical compound.

Today our guests are Charlie Silver and Nigel Beard. Charlie is CEO, and Nigel CTO, of Mission Bio. Mission Bio is a single-cell analysis platform company empowering researchers to cure cancer. They are the first company to deliver simultaneous measurement of the genotype and phenotype at single-cell resolution. In this episode, we talk about the audacious mission at Mission Bio, and how their groundbreaking platform enables a whole new set of questions to be answered in cancer research. We also go deep on potential clinical applications and the future of single-cell multi-omic datasets.

Visit ⁠⁠TPM E17⁠ for highlights and links from this episode.

Reboot Rx is a different kind of biotech startup. Reboot’s mission is to find generic non-cancer drugs that can benefit cancer patients quickly and affordably. And as a not-for-profit, Reboot can stay focused on its mission. Given the number of paradigms Reboot hopes to shift at once, we decided to talk with all three co-founders: CEO Laura Kleiman, COO & CTO Pradeep Mangalath and CSO Catherine Del Vecchio Fitz. Each one provides perspective on their part of the puzzle.

Visit TPM E21 for highlights and links from this episode.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling in precision medicine. We help accelerate the discovery and de-risk the development of novel therapeutics. From heterogeneous data and diverse information stores, we predict with confidence drug targets and biomarkers of tolerance, efficacy and outcome. In this episode we speak with Asim Siddiqui. Asim is the CTO at NuMedii—a data driven drug discovery company. He has deep experience in computational biology, software engineering, next-generation sequencing, and cancer informatics, and is responsible for architecting and applying NuMedii’s AIDD (Artificial Intelligence for Drug Discovery) technology. We talk about leveraging public data for discovery, communicating between data scientists, bench scientists and other stakeholders, and the potential and challenges of using AI to advance drug development.

Today’s guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.

Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.

It has become an iconic name in the field of artificial intelligence for drug discovery.

TPM E44 highlights >⁠⁠⁠⁠⁠⁠⁠

Episode 44 links:

• Najat Khan on LinkedIn
• Recursion

Today’s news is dominated by the corona virus and COVID-19 pandemic. Rightfully so.  But today we’re bringing you a story of another class of viruses, called Phage. Phage are viruses that find and kill bacteria, and Felix is a Bay Area biotech harnessing the power of phage to fight the scourge of antibiotic resistant infections. So join our conversation with founder and CEO, Dr. Rob McBride, from wherever you have socially distanced yourself or locked down on quarantine, and learn about the viruses that are actually saving lives.

Visit ⁠TPM E19⁠ for highlights and links from this episode.